Clinical Policy: Ranibizumab (Byooviz, Cimerli, Lucentis, Susvimo)
Customize your policy alerts
Sign up for Health Net Policy CP.PHAR.186 alerts
Get alerted when Policy CP.PHAR.186 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity criteria, dosing limits, prior authorization and coverage decisions for ranibizumab products (Lucentis, Byooviz, Cimerli, Susvimo) across Commercial, HIM and Medicaid lines of business for Health Net/Centene-affiliated plans.
Added quantity limit of 1 vial/syringe for Lucentis and biosimilars.
Revised Susvimo maximum dose to 100 mg (1 vial) per 6 months per PI.
Simplified FDA-approved indications to show Lucentis and Cimerli are additionally indicated from Byooviz for DME and DR.
Coverage and Medical Necessity Criteria
Initial Therapy — Ophthalmic Disease Other Than DME/DR
Covered when ALL of the following are met for ophthalmic diseases other than DME/DR:
Initial Therapy — DME and DR
Covered when ALL of the following are met for Diabetic Macular Edema (DME) or Diabetic Retinopathy (DR):
Continued Therapy — Continued therapy (all indications)
Continued therapy (all indications) — member must meet one of the following and product-specific rules:
Initial and ongoing coverage criteria (dosing/product limits)
Coverage references dosing and indications aligned to FDA-labeled uses and policy updates; prior authorizations and quantity limits apply.
Policy update added quantity limit and revised Susvimo maximum per product information.
Coverage is limited to FDA‑approved indications for ranibizumab products. Non‑FDA approved indications are not covered under this policy unless the provider submits sufficient documentation of efficacy and safety and the request meets the applicable off‑label use policy for the member’s line of business (see CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid). If the requested use is for a drug on or off the formulary and the criteria here do not apply, providers should follow the referenced formulary, non‑formulary, or off‑label policies for coverage determination.
Inclusion of a procedure or HCPCS/J/Q code in this policy does not guarantee coverage. Providers must follow the most current professional coding guidance and payer billing instructions when submitting claims. State‑specific Medicaid billing rules or other plan‑specific coding directions may supersede the codes listed here; when in doubt, reference the applicable plan’s coding resources.
Uses that are not FDA‑approved and that lack sufficient supporting documentation of safety and efficacy per the off‑label use policies are not authorized. Requests for off‑label indications must meet the criteria and evidence requirements in the referenced off‑label use policy for the appropriate line of business; absent that documentation, coverage will be denied.
Policy history documents that the program historically redirected use toward intravitreal bevacizumab (Avastin) to limit use of other, more costly agents. Over time this redirection language was revised — from a preference or “must use” approach to a step‑therapy requirement that typically requires failure of intravitreal bevacizumab unless contraindicated or clinically significant adverse effects are documented.
Codes, Doses, and Product Limits
| 1.25 mg | bevacizumab intravitreal injection dosing referenced as therapeutic alternative (Avastin) — 1.25 mg every 4 weeks |
| 0.5 mg | ranibizumab dose for RVO or mCNV and for Byooviz/Cimerli/Lucentis for some indications (0.5 mg monthly) |
| 0.3 mg | ranibizumab dose for DME/DR with Cimerli or Lucentis (0.3 mg monthly) |
| 2 mg | Susvimo implant dose for nAMD: 2 mg per 6 months (one 100 mg/mL vial per 6 months) |
| 100 mg | Susvimo vial amount referenced for some dosing statements (100 mg per vial, policy notes up to 100 mg per 6 months) |
Authorization, Documentation, and Billing Actions
Prior authorization required; document diagnosis, ophthalmologist involvement, and bevacizumab failure
Prior authorization is required for ranibizumab products; provider must document the member’s diagnosis, that the drug was prescribed by or in consultation with an ophthalmologist, prior failure of intravitreal bevacizumab unless contraindicated or clinically significant adverse effects, and that the requested dose does not exceed product-specific limits.
- Document diagnosis (e.g., nAMD, RVO-related macular edema, mCNV, DME, or DR).
- Document ophthalmologist involvement (prescribing or consultation).
- Document prior failure of intravitreal bevacizumab or contraindication/adverse effect.
- Confirm requested dose is within product-specific maximums.
Prior authorization requirement for ranibizumab products and biosimilars; follow PA and coding limits
Prior authorization processes apply to ranibizumab and its biosimilars; providers must follow PA submission requirements and adhere to the updated quantity and dosing limits (including HCPCS/J- and Q-code implications noted in the policy).
- Follow payer PA process when requesting Lucentis, Byooviz, Cimerli, or Susvimo.
- Adhere to quantity limit of 1 vial/syringe per request for Lucentis and biosimilars (policy update).
- Use appropriate HCPCS/J/Q codes referenced by the policy when submitting requests/claims.
Bevacizumab step: document failure or contraindication
Step therapy requires documented failure of intravitreal bevacizumab (Avastin) before approval of ranibizumab products, unless bevacizumab is contraindicated or causes clinically significant adverse effects.
- If bevacizumab was tried, include documentation of treatment and why it failed (lack of efficacy or intolerable adverse effects).
- Note: IV formulations of Avastin, Mvasi, and Zirabev will not be approved for intravitreal use.
Step therapy history — redirection converted to 'failure of bevacizumab' requirement
Policy history shows prior redirection to bevacizumab intravitreal solution was used historically and was revised to a requirement of documented failure of bevacizumab before approving other agents.
- History: redirection language converted from 'must use' to 'failure of bevacizumab' approach.
- Recent updates reflect conversion to failure-based step therapy rather than mandatory redirection.
Required documentation: submit office notes, test results, imaging, and treatment history
Providers must submit supporting clinical documentation with PA requests, such as office chart notes, lab results, imaging (OCT/fluorescein angiography), and prior treatment records demonstrating the member meets all approval criteria.
- Include documentation of prior bevacizumab treatment and response or contraindication.
- Provide evidence of diagnosis and ophthalmologist consultation.
Document dose, product, formulation (vial vs prefilled syringe) and administration details
Document the specific indication, the exact administered product and formulation (vial or prefilled syringe), and the administered dose (e.g., 0.5 mg or 0.3 mg intravitreal injection; Susvimo implant/refill intervals and vial strength).
- Record product name (Lucentis, Byooviz, Cimerli, Susvimo) and HCPCS/J/Q code where applicable.
- Record dose and formulation (e.g., 0.5 mg/0.05 mL vial, 0.3 mg/0.05 mL prefilled syringe, Susvimo 100 mg/mL vial and refill interval).
Documentation/Indication denial risk — missing evidence or non‑FDA uses may be denied
Failure to provide the required documentation that the member meets all approval criteria may result in denial; coverage is not authorized for non‑FDA indications unless off‑label policy criteria are met.
- Missing documentation of prior bevacizumab failure, diagnosis, ophthalmologist involvement, or dosing within limits can trigger denial.
- For non‑FDA uses, include evidence meeting off‑label policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) to avoid noncoverage.
Coding and coverage mismatch — follow up‑to‑date coding guidance to avoid denials
Claims and prior authorization requests may be denied if coding guidance is not followed; inclusion of codes in the policy does not guarantee coverage—providers should use current professional coding guidance and the policy‑referenced codes when applicable.
Clinical Background
Ranibizumab and its biosimilars are vascular endothelial growth factor (VEGF) inhibitors indicated for multiple retinal neovascular and edematous conditions. Depending on the product, FDA‑labeled indications include neovascular (wet) age‑related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), and diabetic retinopathy (DR). Clinical trials summarized in the literature demonstrate ranibizumab improves visual acuity outcomes compared with older therapies and is associated with established safety profiles that inform product‑specific dosing and monitoring.
Clinical Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.